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Abstract
We reported previously that a proportion of natural CD25
+ cells isolated from the PBMC of HCV patients can further
upregulate CD25 expression in response to HCV peptide stimulation in vitro, and proposed that virus-specific regulatory T
cells (Treg) were primed and expanded during the disease. Here we describe epigenetic analysis of the FOXP3 locus in HCV-
responsive natural CD25
+ cells and show that these cells are not activated conventional T cells expressing FOXP3, but hard-
wired Treg with a stable FOXP3 phenotype and function. Of ,46,000 genes analyzed in genome wide transcription
profiling, about 1% were differentially expressed between HCV-responsive Treg, HCV-non-responsive natural CD25
+ cells
and conventional T cells. Expression profiles, including cell death, activation, proliferation and transcriptional regulation,
suggest a survival advantage of HCV-responsive Treg over the other cell populations. Since no Treg-specific activation
marker is known, we tested 97 NS3-derived peptides for their ability to elicit CD25 response (assuming it is a surrogate
marker), accompanied by high resolution HLA typing of the patients. Some reactive peptides overlapped with previously
described effector T cell epitopes. Our data offers new insights into HCV immune evasion and tolerance, and highlights the
non-self specific nature of Treg during infection.
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Introduction
Hepatitis C virus is a small positive sense single stranded RNA
virus, which causes persistent infection that leads to cirrhosis,
cancer and liver failure. In the acute phase of the infection, the
host usually mounts strong CD4
+ and CD8
+ T cell responses, but
this wanes in the next few months during the transition to
persistence (reviewed in reference [1]). Typically, in persistently-
infected patients, the frequency of HCV-specific IFNc-producing
effector T cells is low (usually ,0.3% of PBMC by ELISPOT) and
that of IL2-producing cells is even lower [2]. T cells, particularly
CD4
+ T cells, proliferate poorly in response to HCV antigens [3],
although CD8
+ T cells proliferate slightly better (Li and Gowans,
unpublished data). The reason behind the lack of adequate
immunity to HCV in human is not well understood, although it is
likely to be multi-factorial [1,4].
IL-10 producing type 1 regulatory T cells (Tr1) may play a role
in HCV persistence [5,6], and more recently, several groups
suggested that natural regulatory T cell (Treg, a different type of
suppressor cell to Tr1) may be also important [7,8,9,10]. The
frequency of circulating CD4
+CD25
+ cells (the cell population in
which Treg are predominantly contained [11]) in the blood of
HCV carriers was higher than in healthy donors and individuals
who had resolved the infection [7]. In addition, the percentage of
CD4
+CD25
+ cells within the infected liver was much higher than
in the peripheral blood [8]. (A review of this topic was published
recently [12]). One basic property of Treg is that, once activated
via the T cell receptor (TCR), they suppress a wide range of
immune responses in vitro and in vivo in a contact-dependent
manner [11]. Sugimoto et al. [13] initially showed that depletion
of CD25
+ cells enhanced the proliferation of the remaining
PBMC, while Cabrera et al. [7] and several other groups [8–10]
further showed that CD4
+CD25
+ T cells isolated from patients’
PBMC could suppress the virus-specific CD8
+ T-cell response,
suggesting that this population contains HCV - specific Treg. The
suppressor function of CD4
+CD25
+ T cells in response to
polyclonal stimuli was further analysed recently in a longitudinal
acute phase HCV cohort [10], and it was found that Treg from
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either those from patients who resolved the infection spontane-
ously or from uninfected healthy donors. In summary, these
studies supported the concept that progression from acute to
persistent infection is associated with functional changes in the
Treg compartment. It is currently unknown, however, to what
extend the total Treg pool in HCV-infected individuals is HCV-
specific or how Treg react to viral infection as part of the adaptive
immune response.
Our group has previously reported [14] that a proportion of
natural CD25
+ cells isolated from the PBMC of HCV patients
substantially upregulated CD25 expression in response to HCV
peptide stimulation in vitro, and we proposed that virus-specific
Treg were primed and expanded during the disease. Somewhat
disturbingly, the frequency of the hypothetical HCV-specific Tregs
far exceeded the well-documented low frequency of IFNc
producing anti-viral effector T cells in chronic infection [1],
prompting us to seek more insight to these cells in this study.
Results
CD25 expression levels become less homogenous
among natural CD25
+ cells during culture
When the CFSE-CD25
+/CD25
2 co-culture from patients was
stimulated for 5 days with the HCV peptide pool (pp), CD25
expression on the CFSE
+ fraction was sustained or up-regulated
compared to the non-antigen stimulated control (Figure 1A). This
observation is reproducible and statistically significant (p,0.05)
(Figure 1B). When healthy donor cells were cultured under the
same conditions, the CD25 expression profile in the HCVpp
culture was similar to that of the non-antigen control (Figure 1A,
right panel and Figure 1B). In healthy donors, the baseline level of
CD25 expression was sometimes higher (Figure 1B) compared to
HCV patients, but there were no major differences between
baseline and HCV pp stimulation. Consistent with the manufac-
turer’s technical datasheet, freshly isolated cells expressed more
homogenous and intermediate levels of CD25 (Figure S1). These
data supported our previous observation with core and NS5
peptides [14], that a proportion of natural CD25
+ cells can sustain
and/or up-regulate CD25 expression (now termed CD25
+/ q cells)
in the presence of HCV peptides and this phenomenon is likely to
be disease specific.
Epigenetic modification of FOXP3 locus in
HCV-responsive natural CD25
+ cells
The transcription factor FOXP3 plays a critical role in the
development and function of natural Treg, but in humans this
molecule is also transiently expressed by activated conventional T
cells [15,16]. We have recently shown that epigenetic DNA
modification of an evolutionarily conserved element within the
FOXP3 locus, named Treg-specific demethylated region (TSDR),
correlates with a stable Treg phenotype [17]. In the current study,
we applied this principle to determine whether the CD25
+/ q cells,
which were previously shown to express FOXP3 [14], are Treg or
activated conventional T cells.
HCVpp stimulated CFSE-CD25
+/CD25
2 co-cultures were
FACS sorted on day 5 into 3 fractions (Figure 2A): CD25
+/ q cells
(P5, .95% of which are CD4
+, Figure S2), CD25
low (P6) and
conventional T cells (P7). Analysis of DNA purified from the above
sorted cells by bisulphate sequencing revealed (Figure 2B, left) a
highly demethylated TSDR in the HCV-responsive fraction
(CD25
+/ q cells, P5), which suggest that these cells are true Treg
with stable FOXP3 expression and function. As expected, the
TSDR in the conventional T cell fraction (P7) remained highly
methylated. The TSDR in the HCV-non-responsive fraction
(CD25
low cells, P6) showed various degrees of demethylation,
which reflects a mixed population of known or unknown cell types.
Some P6 cells expressed FOXP3 (Figure 2B, right), but the
proportion varied greatly among patients (from ,5% to ,40%,
data not shown).
Global gene expression profiling for HCV-responsive Treg
To further understand the putative disease-associated CD25
+/ q
Treg, genome-wide transcriptional profiles were generated on
RNA isolated from the cells, cultured and sorted as described
above (Microarray datasets are deposited in Gene Expression
Omnibus under series record GSE16576, and can be reviewed via
the following link: http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE16576). The Illumina platform was chosen because
it requires only 100ng RNA, and given that cell numbers in P5
(CD25
+/ q) and P6 (CD25
low, or HCV-non-responsive natural
CD25
+ cells) were limited, this allowed us to analyse each patient
individually without pooling samples and thus permit rigorous
statistical analysis. Of ,46,000 genes (or probe sets) analysed, 307
genes were differentially expressed between P5 and P6, followed
by 272 genes differentially expressed between P5 and P7 and 155
genes between P6 and P7 (Figure 3A). Some transcript changes
were found in more than one comparison (Figure 3B). This
constitutes ,1% of the entire known transcriptome, while the
remaining ,99% of genes were expressed at similar levels by all
three T cell fractions. Table S1 provides the full list of genes that
were differentially expressed in P5 compared to P6 or P7 (Table
S1-A), and in P6 compared to P7 (Table S1-A). Figure 3C shows
selected examples of these genes and demonstrates that the data
are highly reproducible.
The key Treg signature genes, such as FOXP3, GITR, CD25,
IL7R and CTLA4 were differentially expressed as expected
among the 3 fractions (Table 1 and Figure 3C) and provide
confidence that the experimental system was able to generate
quality data. A number of transcription factors (Table 1 and Table
S1) were among the differentially expressed genes. This is not
particularly surprising because studies in mice suggested that
transcription factors are among the genes regulating or regulated
by Foxp3 [18].
Ingenuity Pathway Analysis (Ingenuity Systems, www.ingenuity.
com), a literature based online annotation tool, was used to identify
Author Summary
Hepatitis C virus persistently infects ,3% of the world
population, leading to life threatening liver diseases and
liver failure. It is not well understood why the human
immune system often fails to clear the virus, although it is
likely multi-factorial. It is accepted that effector T cells are
critical for clearing infections, but their function can be
suppressed by the somewhat elusive regulatory T cells.
Our hypothesis, supported by new data, is that a
proportion of the regulatory T cells are specifically
stimulated by the virus and that these cells are a stable
cell population. We find evidence that these suppressive
cells have a distinct set of genes activated and importantly
might have a survival advantage over effector T cells,
which helps to explain why natural regulatory T cells may
influence the outcome of HCV infection. We propose that
the new information provides a better explanation of
chronic HCV infection and will let us focus on the key
experiments to test the hypothesis and to design better
treatments.
Analysing HCV-Specific Natural CD25
+ T Cells
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(Figure S3 and S4). This is the first study in which the putative
HCV-specific Treg (CD25
+/ q) were analysed against the putative
non-HCV-specific Treg (P6), as well as conventional T cells (P7).
Most interestingly, a group of genes (Table 1, Figure 3C and Table
S1) that were known to be implicated in T cell survival or
proliferation (within the top function, immune response, in Figure
S3) were differentially expressed by P5 compared to P6 and/or P7.
This includes the up-regulation of BCL2 and BCL2L1 (anti-
apoptosis), TNFRSF1B and FLT3LG (promote T cell proliferation
and activation), IL7 (T cell survival signal) and IL32 (a cytokine
released following T cell activation, reviewed in reference [19]), and
the down-regulation of the pro-apoptosis gene BMF. This pattern
suggests that cells in P5 are likely to be more activated and perhaps
have a survival advantage over cells in P7 and/or P6. Figure S3
summarizes the major networks of interactions between these
affected genes.
It is known (reviewed in [11]) that Treg must be activated via
their TCR to gain suppressor function, and we applied this
principle to test the activation status of CD25
+/ q cells (N=3). We
used CD4
+ conventional T cells as control because the CD25
+
cells isolated from PBMC were almost exclusively CD4
+ (Figure
S2). The responder cells were a short term autologous CD8
+ T cell
line driven by HCVpp. The sorted cells (see Figure 4A for a simple
illustration and Figure 2A for technical details) were added to
responder cells at a ratio of 1:2 and cultured for 7 days. CD25
+/ q
cells strongly suppressed HCV-specific CD8
+ T cell proliferation,
as measured by Ki67 expression on the responder cells (as the
Figure 1. A proportion of natural CD25
+ from patients, but not healthy donors, can sustain or up-regulate CD25 expression
following in vitro HCV peptide stimulation. (A) The CFSE-CD25
+/CD25
2 co-cultures were stimulated with the HCV peptide pool and analysed on
day 5, gating on lymphocytes. The number in the upper right corner indicates the percentage of CD25
+ cells within the total CFSE
+ population.
(Representative data of N=5 patients and N=4 healthy donors). (B) Summary of data from all donors. P value was calculated using student T test.
doi:10.1371/journal.ppat.1000707.g001
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assay is more sensitive than 3HTdR incorporation in assays with
low proliferating cell numbers). Cells from P6 suppressed to a
lesser degree, reflecting that this was a mixed population of various
cells of unknown nature, while conventional CD4
+ cells had no
suppressive activity (Figure 4B). These results were confirmed in
studies with cells from two additional patients (data not shown). In
addition to suppression, P5 also expressed a higher level of IL32
mRNA than P6 (Table 2, in 3 of 4 patients) and P7 (Table 2, in 4
of 4 patients), analysed by qRT-PCR. The role of IL32 in HCV
infection is unknown and requires future investigation. Taken
together, P5 at the population level correlated with cytokine
production and suppressor function, although at present we do not
have a reporter molecule that could independently validate the
TCR recognition of HCV antigens at the single cell level, a
challenging area that is currently being investigated in our
laboratories.
A number of genes related to B cell phenotype and function,
such as toll like receptors, CD19, CD72, CD86, BLNK, etc. were
up-regulated in P6. Interestingly, the same category of genes was
also up-regulated in healthy donor natural Treg compared to
conventional T cells (Barry, unpublished data). The implication of
this is currently unclear. Genes related to CD8
+ T effector cell
functions (such as CD8, perforin and granzymes) were upregulated
Figure 2. Methylation analysis of the FoxP3 locus in sorted cell populations. (A) Gates for sorting and post-sort purity. The co-cultured cells
from a patient were sorted at day 5, based on CD25 expression, into 3 fractions: P5 (CFSE
+CD25
+), P6 (CFSE
+CD25
2) and P7 (conventional T cells,
CD3
+CFSE
2) using BD FACSAria. Note that a CD3 gate was introduced to the CFSE
2 fraction in addition to the lymphocyte gate. This sorting strategy
was applied to both methylation (N=5) and microarray (N=6) experiments. (B) Methylation analysis. The left panel shows the methylation status of
the TSDR in the sorted populations P5, P6 and P7. Each block represents a CpG motif of the TSDR (Amp5) within the FOXP3 locus. The methylation
level is colour coded (yellow=0% methylation, blue=100% methylation). The panel on the right shows the FOXP3 record of sorted cell fractions for
this patient. (Representative data of N=5 patients).
doi:10.1371/journal.ppat.1000707.g002
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PLoS Pathogens | www.plospathogens.org 4 December 2009 | Volume 5 | Issue 12 | e1000707Figure 3. Microarray data. (A) The overall pattern of transcript changes in dot plots; each dot represents a gene. The cut-offs used were: Diff Pval
,0.05 and fold change .1.5. (B) Venn diagram showing the number of genes that were differentially expressed between P5 and P6, P5 and P7, and
P6 and P7. Note that the transcription levels of certain genes are changed in more than one comparison. (C) Typical examples of differentially
expressed genes, each data point represents the average value of all technical replicates (background subtracted and normalized) of one patient. The
data shown in (A) and (B) were derived from statistical calculations based on a sample size of N=6, whereas the data shown in (C) represent the data
generated from individual patients.
doi:10.1371/journal.ppat.1000707.g003
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Group, gene symbol AVG_SIGNAL P5/P6 Log
2FC Diff Pval P5/P7 Log
2FC Diff Pval
P5 P6 P7
Treg markers or associated
CD127 2767 7597 8349 21.457 1.9E-08 21.593 3.3E-07
CD40L 148 308 291 21.054 2.1E-03 20.974 7.9E-03
CTLA4 4317 1244 939 1.795 5.0E-03 2.201 1.3E-03
FOXP3 84 22 19 1.904 3.7E-07 2.172 9.7E-08
GITR 226 36 42 2.652 2.7E-02
GJB6 85 12 7 2.870 2.8E-03 3.535 1.3E-03
IL2RA 2104 181 155 3.541 4.0E-08 3.767 8.4E-08
IL2RB 5469 2362 3580 1.211 8.3E-06
Apoptosis
BCL2 2400 984 505 1.287 5.7E-08 2.249 1.6E-16
BCL2L1 657 275 351 1.253 7.7E-05 0.905 9.4E-03
BMF 79 162 63 21.038 4.3E-02
CD120b 4965 2177 1882 1.190 4.3E-07 1.399 1.3E-07
Cytokines
IL7 42 36 1 5.034 1.0E-02
IL15 87 280 189 21.678 0.001
IL32 1984 1149 1044 0.788 3.6E-03 0.926 6.6E-04
Killing
FASLG 13 51 137 21.989 2.7E-03 -3.403 1.5E-02
GZMA 325 717 4537 -3.802 2.6E-34
GZMK 258 655 3450 -3.743 2.6E-34
KLRD1 29 96 819 21.709 1.3E-02 -4.804 1.4E-07
KLRK1 45 203 1378 22.172 2.2E-03 -4.937 2.6E-34
PRF1 836 488 2574 0.775 1.3E-02
Transcription factors
CITED4 618 194 214 1.672 2.8E-04 1.527 7.0E-04
E2F5 214 555 180 21.372 9.1E-03
PCAF 2698 1710 1607 0.658 3.0E-02 0.748 1.4E-02
PFTK1 71 248 57 21.806 1.6E-02
UBTF 144 188 250 20.798 4.7E-02
ZNFN1A4 685 108 69 2.668 7.1E-17 3.317 1.7E-20
Cell cycle, proliferation
FLT3LG 863 384 392 1.168 2.5E-04 1.140 7.9E-04
TPD52L1 51 15 9 1.747 4.2E-04 2.520 6.9E-06
B cell function associated
BLNK 84 405 67 22.265 3.3E-03
CD19 389 2026 405 22.379 1.4E-08
CD72 161 656 242 22.023 5.2E-03
FCRL1 84 420 86 22.329 2.5E-12
FCRLM1 473 2371 447 22.327 1.8E-06
Others
ATP1B1 320 149 108 1.101 3.3E-02 1.574 1.8E-03
CCL5 (RANTES) 116 639 3487 22.465 1.7E-06 24.913 3.9E-09
CCR7 3351 4220 6376 20.928 6.6E-03
CD161 694 1771 1633 21.351 1.7E-02
CISH 2649 399 247 2.730 3.1E-15 3.423 3.0E-18
CLAUDIN2 18 28 58 21.660 3.1E-02
Analysing HCV-Specific Natural CD25
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2FC Diff Pval P5/P7 Log
2FC Diff Pval
P5 P6 P7
CXCR7 258 137 120 0.913 1.5E-03 1.103 3.0E-04
GNG2 583 354 339 0.722 6.1E-02 0.783 4.1E-02
IFNAR2 1199 844 721 0.735 2.0E-02
IL18RAP 349 349 1291 21.887 1.0E-04
TLR6 28 80 25 21.514 1.7E-03
TLR9 55 107 48 20.961 1.1E-02
TLR10 98 574 95 22.554 1.4E-12
IRF4 127 81 45 1.492 4.9E-04
IRF8 716 2410 927 21.751 2.2E-04
F2R (thrombin receptior) 14 48 148 21.822 7.8E-04 23.440 1.7E-04
PDL1 157 92 60 1.390 6.6E-05
PTGER2 (PGE2) 935 441 254 1.882 2.8E-03
SOCS2 746 129 48 2.527 3.2E-02 3.956 6.7E-03
TGFBR2 836 1264 1499 20.843 2.6E-02
TGFBR3 332 592 999 21.592 1.5E-02
Footnotes: The AVE_SIGNAL is background subtracted hybridization fluorescent intensity (see materials and methods), and all genes have a detection P value,0.001 for
P5 (data not shown). For differential analysis, the cut off was set at diff Pval ,0.05 and fold change .1.5 (Log2FC.0.58 or ,20.58), and the data space was left empty
when this criterion was not met. (Please see Table S1 for the full list of differentially expressed genes).
doi:10.1371/journal.ppat.1000707.t001
Table 1. Cont.
Figure 4. CD25
+/ q cells are suppressive. (A) A simple illustration of the CD4 gate. The co-cultured cells from the patient were sorted as described
in Figure 2A, except that a CD4 gate was introduced in addition to the CD3 gate, into P5 (CFSE
+CD25
+), P6 (CFSE
+CD25
2) and P9 (CD4
+CD3
+CFSE
2)
fractions. (B) The in vitro suppression assay. The target cells were a HCV-specific CD8 T cell line (comprised of autologous CD8 T cells and monocytes,
cultured for 5 days in the presence of HCVpp). 1610
5 of the sorted cells (P5, P6 or P9) were mixed with 2610
5 target cells and 2610
4 feeders
(autologous iDC). This co-culture was stimulated with HCVpp for 7 days, and analysed for Ki67 expression by flow cyometry, gating on CD8
+ target
cells. (Representative data of N=3 independent experiments using different donors).
doi:10.1371/journal.ppat.1000707.g004
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the only fraction which contained CD8
+ T cells, while the original
CD25
+ fraction (now P5 and P6) contained mainly CD4
+ cells
(Figure S2).
Identity of putative Treg epitopes
The HCV NS3 protein has been proposed as a suitable
immunogen for vaccine development [20]. The NS3 peptide array
(provided by BEI resources, ATCC) consists of 97 overlapping
peptides that cover the length of this protein (Table S2 lists the
sequence of each peptide). We tested each of the peptides for their
ability to induce CD25
+/ q cells following individual peptide
stimulation (N=8). Our working hypothesis is that such a
phenomenon directly or indirectly reflects Treg recognition of
HCV antigens.
Comprehensive HLA typing of all common loci including class I
(HLA-A, B, C) and class II (HLADRB1) was performed for each
patient by DNA-based sequencing methods (Figure 5 and Table
S3). We found, as expected, that the HLA diversity amongst
individuals was high, which may explain why the reactive peptides
were not overtly consistent among patients. While the exact
location varied among patients, for a given patient, only a few
peptides could induce CD25 up-regulation (Figure 5), which is
consistent with our earlier findings with the HCV core protein
[14]. Some of the reactive peptides are located close to or
overlapped with previously described T cell epitopes (Table S4).
The implications of this need to be further investigated.
The mechanisms of the positive responses are unknown but our
data suggested that it could be related to the HCV-specific nature
of Treg. To test this working hypothesis, we designed a HLA
(DRB1*1301)-peptide (WKCLVRLKPTLHGPTPLL, the p92)
tetramer, which is, to our knowledge, the only HCV HLA class
II -peptide tetramer developed based on non-T-helper responses.
Compared to a HLA mismatched control, more tetramer
+ cells
were detected in the patient with DRB1*1301 (7% in SA67
compared to 1.2% in PH 35 in Figure 6A), suggesting the staining
signal is likely true. The control tetramers 0701-p92 (mismatched
HLA loaded with the same peptide) and 1301-empty (the correct
HLA but loaded with no peptide) showed minimal background
staining, further suggesting that the staining is genuine. Impor-
tantly (Figure 6B), a high proportion (.60%) of the tetramer
+
Treg cells were CD25
+, while the vast majority (.90%) of
tetramer
+ T-helper cells were CD25
2, supporting our hypothesis
and also implying that the tetramer
+ T-helper are likely not
functional (given that CD25 is an activation marker for
conventional T cells).
Discussion
Conventional protocols to culture human Treg usually involve
long term expansion in the presence of high doses of rhIL2. We
have previously described a novel co-culture system [14], which
we believe to be more physiological. In this system, PBMC-derived
CD25
+ cells are labelled with CFSE, mixed with CD25
2 cells
from the same donor and finally stimulated with HCV peptides.
This approach, used throughout the current study, allowed us to
identify a HCV-specific response within the natural CD25
+ cell
population by observing their response to HCV antigen with
conventional T cells as an internal control. We found that the
CD25
+ population isolated from PBMC of HCV patients, despite
a failure to proliferate (which is consistent with the literature that
Treg are hypo-proliferative in vitro), responded to HCV peptide
stimulation by sustaining and/or up-regulating CD25 surface
expression, a phenomenon that does not occur, or at least to a
lesser degree, in healthy donors. It is not known if human Treg can
down regulate CD25 expression in vitro in the absence of antigen,
but we think this can not be excluded.
In naı ¨ve inbred pathogen-free mice, CD25
+ cells isolated from
PBL are almost entirely Foxp3
+ natural Treg, but in adult
humans, the CD25 expression level is more heterogeneous, as this
population is expected to contain activated effector T cells and
other known or unknown cell types, particularly during infection.
The transient expression of FOXP3 by activated human
conventional T cells [15,16] further complicates the interpretation
of human data. We found that natural Treg and Treg converted in
vivo under tolerogenic conditions [21] exhibited a completely
demethylated TSDR, whereas activated conventional T cells and
TGF-b induced Treg contained almost 100% methylated CpG
motifs. We therefore proposed the TSDR methylation status as a
reliable criterion for the identification of natural and stable subsets
of induced Tregs [17]. Using the same criteria, we confirm here
that the CD25
+/ q cells in our culture are not activated
conventional T cells or TGF-b converted unstable Treg, but are
‘‘hard-wired’’ stable Treg. Since the origin of human Treg is
unclear [22,23], CD25
+/ q cells could either belong to the natural
Treg lineage, or be converted from peripheral HCV-specific
conventional T cells during the infection, but if it is conversion, the
conversion is thorough, as demonstrated by the epigenetic imprint.
More Treg were found in HCV-infected liver than periphery
blood [24], where a surprisingly high proportion (,80%) of T cells
expressed FOXP3. In vivo expansion of HCV-specific Treg is
possible, as Treg from a HCV-experienced chimpanzee had a
lower TCR excision circle content compared to naı ¨ve animals
[25]. The induction and expansion of HCV-specific Treg could
have profound effects on the quantity and quality of the anti-viral
effector T cell responses.
We next generated gene expression profiles of CD25
+/ q cells
(P5), using CD25
low (P6) and conventional T cells (P7) as controls,
to understand the molecular program that governs the role of
these cells. In addition to typical Treg gene patterns, which are
either consistent with our FACS data or with the literature, P5 also
expressed genes patterns that are less known, such as the survival
profile. In an independent study (Barry, et al, unpublished data) we
generated transcriptional profiles for ex vivo isolated (FACS sorted
CD25
high cells) resting, as well as polyclonal stimulated Treg and
Table 2. Real time RT-PCR detection of IL32 in N=4 chronic
HCV patients.
Patient ID Fraction IL32 relative copy numbers
P5 4.814
PH12 P6 1.153
P7 2.66
P5 7.159
SA76 P6 10.364
P7 1.503
P5 5.225
S07-37 P6 0.807
P7 1.281
P5 33.757
S07-40 P6 4.240
P7 1.290
doi:10.1371/journal.ppat.1000707.t002
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+/CD25
2 co-culture from one patient was stimulated in a 96-
well plate with individual NS3 peptides, genotype matched, and analysed for CD25 expression on day 5. The bar plot shows total fluorescent intensity
(TFI=% x MFI) of CD25
+ cells (R2 within R4) induced by each peptide for this patient. TFI was normalised against the MFI of CFSE
+/CD25
2 population
(upper left quadrant). The dotted line represents the average TFI of all peptides tested and the solid line indicates the cut off (average + 4 standard
errors). (B) Typical plots of reactive and non-reactive peptides. The plot p43/97 depicts the typical profile by a few reactive peptides, whereas p26/97
depicts the lack of response by a majority of the peptides. The positive control was anti-CD3 (0.1 mg/ml final). (C) NS3 mapping data from an
additional 7 patients. PH08 spontaneously resolved the infection and the remainder are chronically infected. S07-04 is genotype 1a and the
remainder are genotype 3a.
doi:10.1371/journal.ppat.1000707.g005
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dataset to the healthy donor dataset provides hints as to
transcriptional changes which could be unique in HCV patients
and thus likely to be associated with HCV infection. BCL2, BMF,
IL7, IL32, CISH, CCL5, CCR7, IFNaR2, IRF4 and IRF8
(Table 1 and Table S1) are all among this ‘‘unique’’ list, and these
genes are known to be critical in regulating cell survival or play
important roles in immune responses against pathogens. Devel-
opment of these data is necessary and is currently ongoing in our
laboratories. It was recently reported that the gene profile of ex vivo
isolated total Treg from HCV patients was very similar to that of
healthy donors [26], as only 5 genes were differentially expressed
between the two and the change ranged from 0.4 to 2.
Interestingly, none of these 5 genes was identified in our
experiments. We think that Treg and non-Treg compartments
are both likely to be affected by the disease, a detail which would
not be revealed by comparing total Treg of patients and healthy
donors.
The continued expression and/or up-regulation of CD25 on a
proportion of Treg in response to HCV peptide stimulation in vitro
is an event associated with HCV infection, because it does not
occur, or is greatly reduced, in healthy donors. This could be a
consequence of TCR engagement by the HCV antigen in the
context of the peptide/HLA complex, a view supported by the
suppression assay data, or alternatively, IL2 (and/or other soluble
factors) produced by effector T cells within the co-culture may
affect CD25 expression on Treg independently of antigen
recognition. In the latter scenario, the apparent antigen specificity
of Treg is likely to reflect the antigen specificity of the effector T
cells. However, the effector frequency within PBMC was very low,
as suggested by the literature (reviewed in reference 2).
Supernatant IL10 and IFN-c levels (measured using Cytokine
Bead Array, BD Biosciences) also did not consistently correlate
with culture conditions viz. the CFSE-CD25
+/CD25
2 co-cultures
and the CD25
2 PBMC cultures with or without antigen, from
patients or from healthy donors (data not shown), and IL2 was
generally below the detection limit (data not shown). This is
consistent with our microarray data, as none of the key gene
signatures for Th1/Th2, Th3 and Th17 (IL2, IL4, IL10, IFNc,
IL12p70, IL17, TGFb, IL6, etc.) were differentially expressed
among the fractions upon HCV antigen stimulation. Thus it is
unlikely that the common soluble factors produced by conven-
tional T cells or other antigen non-specific cells in culture could
determine the apparent Treg responsiveness.
Ideally we should use a Treg-specific activation marker for
epitope mapping, but since there is no such marker we used CD25
as a surrogate marker. In almost every patient, the most reactive
NS3 peptide induced higher CD25 expression on Treg compared
to anti-CD3 (Figure 5B). Given that anti-CD3 induced more
conventional T cells to express CD25 than any of the peptides
(Figure 5B and data not shown), these data support the concept
that soluble factors alone do not completely correlate with the
magnitude of the Treg response, as the level of IL2 in the anti-
CD3 culture must be otherwise sufficient to achieve the highest
CD25 expression. We attempted to match the reactive peptides
against published data on effector T cell epitopes, but found this
difficult, as studies using class II tetramers only focus on a few
epitope/DR pairs, while in studies which did not use tetramers the
HLA typing data were incomplete or missing. Further validation
of the putative Treg epitopes and their HLA restriction are
required, but nevertheless, our data show that the breadth of the
reactivity is rather narrow, while the response itself is robust.
Due to the lack of any Treg specific surface marker and a simple
functional readout for these cells, it has not been possible to
develop tetramers that are restricted to Treg. Using two class II
HLA tetramers previously developed based on T-helper responses,
Heeg et al [27] detected FOXP3
+ cells during acute infection and
reported that the frequency of tetramer
+FOXP3
+ cells was low
and did not correlate with disease progress or outcome. It is
unclear at present how this reflects a global picture of Treg/Teff
balance, as it is not known to what extent the Treg repertoire
overlaps with that of Teff, or if Treg and Teff clones of the same
Figure 6. Tetramer staining. (A) The HCV peptide pool stimulated CFSE-CD25
+/CD25
2 co-culture was harvested on day 5 and stained with the test
tetramer 1301-p92, or control tetramer 1301-empty and 1701-p92. SA67 is a HLA matched donor (DRB1*0101/DRB1*1301) and PH 35 is a HLA
mismatched control (DRB1*1201/DRB1*1601), both chronically infected with HCV gt3a. The numbers indicate the percentage of CD4
+ lymphocytes
within the quadrant. (B) CD25 expression profile of tetramer
+ cells. The numbers indicate the percentage of tetramer
+ cells within the quadrant.
doi:10.1371/journal.ppat.1000707.g006
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Unfortunately, our tetramer data is limited at present and could
not answer these questions. Further studies are required, but since
it is impossible to develop tetramer for every T cell epitope, we
believe that it is important to develop a higher throughput or a
more practical Treg antigen specificity readout so that a more
global picture can be obtained.
This study opens a window to explore the role of Treg and their
target antigens in a chronic viral infection of humans. The target
antigens recognised by the FOXP3
+ lineage in humans are largely
unknownand systemsto guide the discoveryof theseantigens would
benefit future studies in HCV vaccines and immunotherapy.
Materials and Methods
Ethics statement
The study was approved by the Alfred Hospital Ethics
Committee and the Victorian Department of Human Services
Human Research Ethics Committee. Written informed consent
was obtained from each subject.
Subjects
HCV-infected participants (N=31) were recruited from the
Alfred Hospital, Melbourne and from an ongoing study of
hepatitis C virus in the social networks of injecting drug users.
All participants were HCV mono-infected, with either genotype 1a
or genotype 3a viruses, and one participant resolved the infection
spontaneously. A few patients were treated previously (unsuccess-
fully) with interferon/ribavirin and the remainder were untreated.
Healthy donors were represented by local volunteers or blood
donors from the Australian Red Cross Blood Transfusion Service,
Melbourne Branch.
Antigens
The HCV peptide array, which contains 18-mer peptides
overlapping by 11aa covering the entire HCV polyprotein, for
genotype 1a and 3a were provided by BEI Resources, ATCC. A
peptide pool (pp) working stock (containing 100 mg/ml of each
peptide) was prepared in DMSO/RPMI. The final concentration
of HCVpp within the culture was 0.2 mg/ml in initial experiments
and 0.15 mg/ml for subsequent experiments, or as indicated.
Cell culture
PBMC from patients or healthy donor controls were separated
by Ficoll Paque centrifugation and CD25
+ cells were isolated from
PBMC using CD25 microbeads (MiltenyiBiotec) according to the
manufacturer’s instructions. The CD25
+ cells, typically 1–2% of
total PBMC, were labelled with CFSE (Sigma-Aldrich) and mixed
back with unlabeled CD25-depleted PBMC at a ratio 1:10. The
CFSE-CD25
+/CD25
2 co-culture was stimulated with or without
genotype matched HCVpp in RPMI-1640, 2 mM L-glutamine,
100 IU/mL penicillin-streptomycin (Invitrogen) and 5% human
AB serum (MP Biosciences) in 24-well tissue culture plates
(Interpath, Australia). Cells were harvested on day 5 for flow
cytometry analysis or sorting. In some experiments, culture
supernatants were collected prior to cell harvesting for cytokine
analysis at later stage.
Antibodies and flow cytometric analyses
In general, fluorescent dye-conjugated antibodies and isotype
controls were purchased from BD Biosciences. PE-conjugated anti-
human FOXP3, isotype control and FOXP3 staining buffer set were
purchased from eBiosciences. Intra-nuclear staining of FOXP3, as
well as Ki67, was performed according to the manufacturer’s
instructions.
Flow cytometry was performed using a FACScalibur flow
cytometer (BD Biosciences,) and Cellquest software. For data
analyses, an initial lymphocyte gate was set based on SSC/FSC
and additional gates introduced as required. Results are presented
as the percentage, or mean fluorescent intensity (MFI) of positively
stained cells within the gated population.
Sorting
Sorting of HCV peptide-stimulated CFSE-CD25
+/CD25
2 co-
cultures from HCV patients was performed using a FACSaria
located in a PC3 facility. The cultures were sorted on day 5 into 3
fractions as specified, based on their CFSE labelling and CD25
expression. The primary gate was set on lymphocytes based on
SSC/FSC and an additional CD3 gate (for methylation analysis
and microarray) or CD4 gate (for in vitro suppression assay) was
introduced to the CFSE
- population to refine the conventional T
cell population.
FOXP3 DNA methylation analysis
For this series of experiments, we used cells from male patients,
as this overcomes the potential X-chromosomal inactivation of one
FOXP3 allele, which usually affects the methylation analysis of
Treg in females. Genomic DNA was isolated from sorted cells
(Figure 2A) using NucleoSpinTissue XS kit (Macherey & Nagel,
Du ¨ren, Germany) following the protocol for cultured cells.
Bisulfite treatment of genomic DNA was performed as described
previously [28] TSDR-primers (59 to 39 direction) p-TGTT-
TGGGGGTAGAGGATTT and o-TATCACCCCACCTAA-
ACCAA, amplifying Amp5 [17] were used for bisulphite-specific
PCR and sequencing reactions. The primers ‘‘p’’ and ‘‘o’’ produce
amplicons based on the +1 strand.
PCR was performed in a final volume of 25 ml containing 1x
PCR Buffer, 1U Taq DNA polymerase (Qiagen), 200 mM dNTPs,
12.5pmol each of forward and reverse primers, and 7ng of
bisulphite-treated genomic DNA at 95uC for 15 min and 40 cycles
of 95uC for 1 min, 55uC for 45 sec and 72uC for 1 min with a final
extension step of 10 min at 72uC. PCR products were purified
using ExoSAP-IT (USB Corp.) and sequenced using the PCR
primers and the ABI Big Dye Terminator v1.1-chemistry (Applied
Biosystems) followed by capillary electrophoresis on an ABI 3100
genetic analyzer. AB1 files were interpreted using ESME.
RNA purification and microarray analysis
Total RNA from sorted cells (P5=CD25+CFSE+,
P6=CD252CFSE+ and P7=CD3+CFSE2, as illustrated in
Figure 2A) was isolated using RNeasy Kit (QIAGEN Australia)
according to the manufacturer’s instructions. The RNA quality
was ascertained by the Agilent Bioanalyser 2100 using the
NanoChip protocol.
The microarray experiments were performed, according to the
technical manual from Illumina, by the Australia Genome
Research Facility. In brief, 100 ng RNA was amplified using the
Illumina Total Prep RNA amplification kit (Ambion Cat.
No. IL1791) to generate biotinylated cRNA. An aliquot (1.5 mg/
30ml) of the labeled cRNA for each sample, prepared in a probe
cocktail that included GEX-HYB Hybridization Buffer, was
hybridized to an Illumina Sentrix Human-6 Expression Bead-
Chip-v2.0 at 58uC for 16 hours. After hybridization, the chips
were washed, coupled with streptavadin-Cy3 and scanned in the
Illumina BeadArray Reader. The scanner operating software,
BeadStudio, converts the signal on the array into a TXT file for
downstream analysis.
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Data analysis and visualization were performed using Bead-
Studio Gene Expression Module v3.3 software (Illumina Inc., San
Diego, CA). With Illumina gene expression array, each probe is
measured at least 30 times independently on random distributed
beads. This large number of technical replicates allows robust
estimation of the hybridization intensity and the measurement
error for each probe. The signal for each probe or probe set (gene)
was averaged and the background (the average signal from the
large number of randomly distributed negative control beads)
subtracted, and then normalized using quantile algorithms that
account for variations between probes and between chips. A
detection P value, calculated by comparing the distribution of the
transcript signal to that of the negative control signal, was set at
#0.001 to identify transcripts that were expressed (with a
confidence of $99.9%) above background. Genes with detection
P value#0.001 in at least one of the three fractions were selected
for further analysis. To detect changes in gene expression between
samples, the differential P value (Diff Pval) was calculated using the
Illumina custom error model, which allows 5% false discovery rate
being automatically adjusted. The cut off for the Diff Pval was set
at #0.05 (a confidence of $95% that the given gene is expressed
at different levels between the sample and control).
We used the Ingenuity Pathway Analysis online software
(Ingenuity Systems, www.ingenuity.com) to help further group
the genes in term of networks and functions.
Real time RT-PCR
RNA was isolated from sorted cells as above. Real time RT-
PCR assay was performed using Mx3000P QPCR system (Agilent
Technologies). The gene expression assays for IL32 and house
keep control GAPDH, as well as One-Step Master Mix Reagents,
were purchased from Applied Biosystems (Foster City, CA, USA).
The cycle conditions are 30 min at 48uC for cDNA synthesis,
10 min at 95uC, followed by 50 cycles of 15 sec 95uC, 60uC 1 min.
Data were analysed using MxPro software supplied by the
manufacturer.
In vitro suppression assay
The co-culture was sorted by FACSAria to CD25
+CFSE
+
(hypothetical HCV-specific Treg), CD25
2CFSE
+ (Treg of other
specificity and other unavoidable contaminating cells) and
CD4
+CFSE
2 (conventional CD4
+) in a PC3 facility. The target
cells were represented by an autologous HCV-specific CD8
+ T cell
line, for which an equal number of CD8
+ T cells and CD14
+
monocytes were mixed and cultured in the presence of 0.15 mg/ml
HCVpp for 5 days. The in vitro assay was set up in U-bottom 96-
well plates in triplicate. Each well, in a final volume of 200 ml,
contained 1610
5 sorted cells, 2610
5 target cells and 2610
4 feeder
(autologous immature dendritic cells generated as described
previously [29]) and the antigens HCVpp (0.1 ug/ml final of
each peptide). At the end of the culture period (day 7), cells were
pooled from the triplicate wells, stained for Ki67 expression and
analysed by flow cytometry, gating on CD8
+ lymphocytes (note
that the sorted cells in this experiment were CD4
+).
NS3 Treg epitope mapping
The CFSE-CD25
+/CD25
2 co-cultures were set up essentially
as described above, except in a 96 well format, containing
2610
5cells in 200 ul medium. Each individual NS3 peptide (Table
S1), genotype-matched, was added to each different well at
10 mg/ml final. Anti-CD3 (clone 32-2A2, Mabtech) was used
as a positive control at 0.1 mg/ml final. The cultures were
harvested on day 5 and analysed for CD25 expression by flow
cytometry. The criteria for reactive peptides were described
previously [14].
Tetramer staining
The p92, WKCLVRLKPTLHGPTPLL, is located towards the
C terminal of NS3 of HCV genotype 3a (Table S1). PE conjugated
HLA class II-peptide tetramer complexes (DRB1*1301-p92,
DRB1*0701-p92 and DRB1*1301-empty) were synthesized at
the Benaroya Research Institute, USA. For staining, the CFSE-
CD25
+/CD25
2 co-culture was harvested at day 5, washed and
resuspended in fresh RPMI medium (same as for culture but
without HCV peptides) at 1610
5 cells in 50 ul per well. To each
well 1 ul of a tetramer was added and the cells incubated for 3 h at
37uC, then 30 min at 4uC to stain surface molecules CD25 and
CD4.
HLA genotyping
High-resolution HLA Class I and II typing was performed by
direct DNA sequencing methods as previously described [30].
Ambiguities were resolved following sequencing with allele-specific
subtyping primers. Sequence electropherograms were analysed
using Assign
TM (Conexio Genomics). Allele assignment was based
upon identity at exons 2 and 3 and consistently allocated for the
most common expressed allele in the relevant population.
Supporting Information
Table S1 Full list of differentially expressed genes
Found at: doi:10.1371/journal.ppat.1000707.s001 (0.35 MB
PDF)
Table S2 NS3 peptide array used in the current study
Found at: doi:10.1371/journal.ppat.1000707.s002 (0.04 MB PDF)
Table S3 HLA typing data
Found at: doi:10.1371/journal.ppat.1000707.s003 (0.07 MB PDF)
Table S4 NS3 T cell epitopes found in the literature.
Found at: doi:10.1371/journal.ppat.1000707.s004 (0.08 MB PDF)
Figure S1 CD25 and FOXP3 expression profile of freshly
isolated CD25
+ cells. Freshly isolated CD25
+ cells were stained for
CD25 (surface) and FOXP3 (intracellular), followed by flow
cytometry analysis gating on CD3
+ lymphocytes (representative
data from N=3 HCV patients).
Found at: doi:10.1371/journal.ppat.1000707.s005 (0.05 MB
PDF)
Figure S2 CD4 expression on day 5 of the co-culture. Plot (A)
shows the lymphocyte gate, (B) shows the CD25 expression on the
lymphocytes, (C) depicts CD4/CD3 expression on CFSE
+CD25
+
population (corresponding to P5, HCV-responsive Treg), (D)
CD4/CD3 expression on CFSE-CD25
+ population (correspond-
ing to P6, HCV-non-responsive Treg) and (E) shows CD4/CD3
expression on CFSE unlabeled CD25 depleted fraction, the CD3
+
cells are conventional T cells, corresponding to P7. (Representa-
tive data from N=5 HCV patients).
Found at: doi:10.1371/journal.ppat.1000707.s006 (0.08 MB PDF)
Figure S3 Ontology clustering using Ingenuity Pathway Anal-
ysis. The differentially expressed genes between P5 and P7 (dark
blue) and between P5 and P6 (light blue bar) were grouped into 9
major functional clusters (x-axis). The y-axis indicates the Fisher’s
exact test P-value, that the higher the bar the less likely the genes
might be found together owning to chance alone.
Found at: doi:10.1371/journal.ppat.1000707.s007 (0.09 MB PDF)
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differentially expressed genes. To construct networks, IPA overlays
the differentially expressed genes with a literature based global
molecular network, and identifies connections between these genes.
A total of 20 statistically significant networks for the P5 vs P7 gene
list, and 21 for the P5 vs P6 list were generated this way. IPA
calculated a score for each network based on the number of
connections betweenthemoleculesand how likely themoleculesare
together by chance, so that the higher the score, the more relevant
the network is to the gene list. The networks shown here are merged
from 3 top-scoring networks for P5 vs P6 (upper panel) and P5 vs P7
(lower panel). The lines between genes represent known direct
(solid) or indirect (dashed) interactions. The coloured shapes
represent up-regulated (red) or down-regulated (green) genes, with
the intensity of the colour proportional to the fold change. The non-
coloured shapes indicate genes that belong to the network in the
Ingenuity knowledge base but were not picked up by our list.
Found at: doi:10.1371/journal.ppat.1000707.s008 (1.45 MB PDF)
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